After regulatory approval, Phase IV trials (post-marketing studies) monitor the treatment’s long-term safety and effectiveness in a broader, real-world patient population. 

Endpoints in this phase include long-term safety, real-world effectiveness, and quality of life (QoL) to ensure that the treatment remains beneficial and safe over time. Phase IV studies also explore optimal use cases, drug interactions, and patient adherence, helping to refine and improve treatment strategies in clinical practice. This is where patient experiences become crucial. Your shared insights about side effects, daily challenges, and treatment outcomes contribute directly to this ongoing research, helping improve care for the entire myeloma community.

Continue reading about how shared patient experiences are reported in clinical trials and how you can contribute to helping researchers understand new treatments in everyday life.